Recombinant Canine GM-CSF Protein

Formulations:
Catalog # Availability Size / Price Qty
1546-GM-025
Product Details
Citations (9)
FAQs
Reviews

Recombinant Canine GM-CSF Protein Summary

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED50 for this effect is 1-4 ng/mL.
Source
E. coli-derived canine GM-CSF protein
Ala18-Lys144
Accession #
N-terminal Sequence
Analysis
Ala18
Predicted Molecular Mass
14.2 kDa

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1546-GM

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

1546-GM/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: GM-CSF

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3 - 5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha -helices (8 - 10). Mature canine GM-CSF shares 49% - 57% amino acid sequence identity with mouse and rat GM-CSF and 69% - 72% with feline, human, and porcine GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha (13). The activity of GM-CSF is species specific between human and mouse, although human GM-CSF is active on canine cells (14, 15).

References
  1. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
  2. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509. 
  3. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163. 
  4. Cao, Y. (2007) J. Clin. Invest. 117:2362.
  5. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
  6. Heuser, M. et al. (2007) Semin. Hematol. 44:148.
  7. Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
  8. Kaushansky, K. et al. (1992) Biochemistry 31:1881.
  9. Diederichs, K. et al. (1991) Science 254:1779.
  10. Nash, R.A. et al. (1991) Blood 78:930.
  11. Onetto-Pothier, N. et al. (1990) Blood 75:59.
  12. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9655.
  13. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
  14. Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.
  15. Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26.
Long Name
Granulocyte Macrophage Growth Factor
Entrez Gene IDs
1437 (Human); 12981 (Mouse); 116630 (Rat); 397208 (Porcine); 403923 (Canine); 493805 (Feline)
Alternate Names
colony stimulating factor 2 (granulocyte-macrophage); Colony-stimulating factor; CSF; CSF2; CSF-2; GMCSF; GM-CSF; GMCSFgranulocyte-macrophage colony-stimulating factor; granulocyte-macrophage colony stimulating factor; MGC131935; MGC138897; Molgramostim; molgramostin; Sargramostim

Citations for Recombinant Canine GM-CSF Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

9 Citations: Showing 1 - 9
Filter your results:

Filter by:

  1. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
    Authors: V Konduri, MM Halpert, YC Baig, R Coronado, JR Rodgers, JM Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi, Z Omarbekov, L Seelhoff, V Ravi, L Douglass, WK Decker
    Cancer Gene Ther., 2019;0(0):.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
    Authors: AJ Hernández-, MA Franco-Mol, EE Coronado-C, P Zapata-Ben, EM Gamboa, Y Ramos-Zaya, SE Santana-Kr, C Rodríguez-
    Res. Vet. Sci., 2018;121(0):23-30.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro
    Authors: F Heinrich, A Lehmbecker, BB Raddatz, K Kegler, A Tipold, VM Stein, A Kalkuhl, U Deschl, W Baumgärtne, R Ulrich, I Spitzbarth
    PLoS ONE, 2017;12(8):e0183572.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  4. In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A
    PLoS ONE, 2016;11(11):e0165477.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.
    Authors: Bauer TR, Olson EM, Huo Y
    Gene Ther., 2011;18(6):553-9.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
    Authors: Xiong W, Candolfi M, Liu C
    PLoS ONE, 2010;5(6):e11074.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.
    Authors: Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, Hilgendorf I, Storb R, Freund M, Junghanss C
    Exp. Hematol., 2009;37(1):143-50.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Effects of GM-CSF gene transfer using silica-nanoparticles as a vehicle on white blood cell production in dogs.
    Authors: Choi EW, Shin IS, Chae YJ, Koo HC, Lee JH, Chung TH, Park YH, Kim DY, Hwang CY, Lee CW, Youn HY
    Exp. Hematol., 2008;36(7):807-15.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  9. Preventive and therapeutic effects of gene therapy using silica nanoparticles-binding of GM-CSF gene on white blood cell production in dogs with leukopenia.
    Authors: Choi EW, Koo HC, Shin IS, Chae YJ, Lee JH, Han SM, Lee SJ, Bhang DH, Park YH, Lee CW, Youn HY
    Exp. Hematol., 2008;36(9):1091-7.
    Species: Canine
    Sample Types: Serum
    Applications: ELISA (Capture)

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Canine GM-CSF Protein

There are currently no reviews for this product. Be the first to review Recombinant Canine GM-CSF Protein and earn rewards!

Have you used Recombinant Canine GM-CSF Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review